Vikram Sinai Talaulikar: New Perspectives on GLP-1 Therapies for Obesity Management
Vikram Sinai Talaulikar, Associate Specialist in Reproductive Medicine at UCLH and Hon, shared a post on LinkedIn abour a paper by Francesca Celletti et al. published in JAMA:
“The first issue of New Scientist for 2026 brings a sharp focus on to GLP-1 weight loss medications.
It suggests that weight-loss medications should get cheaper and more accessible (with expiry of semaglutide patents in many countries) and the approval of orforglipron which can be taken in a pill form. Also, there are more promising drugs on the horizon that could produce greater benefits (with more than 100 weight-loss drugs in development).
As the article notes, there are still many unanswered questions about long-term effects, what happens when you stop and the access to these agents.
The world health organisation guidelines conclude that medications alone cannot solve the global obesity burden. The availability of GLP-1 therapies should galvanise the global community to build a fair, integrated, and sustainable obesity ecosystem. Countries must ensure equitable access not only to comprehensive disease management, but also to health promotion and prevention policies and interventions targeting the general population and those at high risk.
As health professionals, we are already seeing more of our patients use GLP-1 agents and the numbers are only set to rise in future. We will have to be prepared and informed about what comes next.”
Title: World Health Organization Guideline on the Use and Indications of Glucagon-Like Peptide-1 Therapies for the Treatment of Obesity in Adults
Authors: Francesca Celletti, Jeremy Farrar, Luz De Regil
Read the full article.
Read more.
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
Oct 11, 2025, 06:44The Global IVF Market Is Set to Reach $65B by 2032 – Meddilink
-
Jan 12, 2026, 16:03New Insights Into Estrogen Receptor Alpha Regulation in the Endometrium – Fertility and Sterility
-
Jan 12, 2026, 15:37From Innovation to Practice: Standards for Embryo Diagnostic Trials – Fertility and Sterility
-
Jan 12, 2026, 14:47HFEA Updates Choose a Fertility Clinic Tool to Improve Success Reporting
-
Jan 12, 2026, 13:14Lucile Ferreux: Prenatal Cadmium Exposure and Its Long-Term Impact on Male Fertility
-
Jan 12, 2026, 13:11This Month’s Fertility and Sterility Unplugged Is Live – Fertility and Sterility
-
Jan 11, 2026, 10:02Hind Hanani: Understanding the Use of Antiphospholipid Syndrome Guidelines Worldwide
-
Jan 11, 2026, 09:58Exploring the Role of Antiphospholipid Antibodies in Severe Preeclampsia – RheumNow
-
Jan 11, 2026, 09:56Adrenal Involvement in Antiphospholipid Syndrome – ARP Rheumatology
-
Jan 11, 2026, 09:52Jamie Agunsday: Understanding Pregnancy-Related Deaths